Market revenue in 2023 | USD 91.4 million |
Market revenue in 2030 | USD 187.6 million |
Growth rate | 10.8% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 66.63% in 2023. Horizon Databook has segmented the Brazil circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
The Brazilian branded generics market is anticipated to witness positive growth over the forecast period owing to factors such as increasing government initiatives and growing target patient population. According to a report, the Brazilian government spent around USD 8.61 billion in the hospital and outpatient care sector in 2020.
The universal health system of Brazil, also known as Sistema Único de Saúde, which intends to provide universal and free healthcare to the public, is expected to drive the adoption of generic drugs in the Brazilian market. The unified healthcare system provides free medications that are on the national list of essential medicines.
However, limited availability of drugs in the public sector presents an opportunity for branded generic manufacturers, as over 30% of the population pays for private health insurance, which was the fourth most important expense in the country as of 2019.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into Brazil circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account